David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360.
Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''.
''I think that's what's exciting - we're really hitting our stride here''.